Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi.

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.